ABSTRACT
Objective To assess the value of MRI combined with CT in the diagnosis of ovarian sex cord stromal tumor (OSCST).Methods The CT and MRI features of 29 cases with OSCST confirmed by pathology were analyzed retrospectively.Results Fibrothecoma in 19 cases showed a solitary round mass with a regular border,solid in 12 cases (63.1％) and cystic-solid in 7 cases (36.9％),calcification in 2 cases,isointense on T1WI and hypointense or slight hyperintense on T2WI with slight enhancement.Granule cell tumor in 9 cases showed a solitary cystic solid mass with thick wall,without nodules on cystic wall,and slight enhancement in the solid parts.Sertoli-leydig cell tumor in 1 case showed a solid mass,slightly hyperintense on T1WI,hyperintense on T2 WI,and obvious enhancement.Conclusion CT and MRI manifestations of OSCST demonstrate some characteristics.Combination with MRI and CT can improve the accuracy of the diagnosis.
ABSTRACT
Objective To evaluate the clinical application of diffusion-weighted MR of low field in hypera-cute cerebral infarction. Methods Conventional MRI and DWI on 0.35T were performed in 15 patients with highly suspicious hyperacute infarction within 6 hours after presenting symptoms. The coincidence between conventional MRI ,DWI and final clinical diagnosis was analyzed to compare the sensitivity and specificity of diagnosis among DWI,ADC and conventional MRI. Results 12 patients were diagnosed as hyperacute cerebral infarction, identical with final clinical diagnosis. 3 patients were negative on DWI ,who were finally diagnosed as TIA by clinical doctors.The high-intensity zone on DWI appeared infarction in following CT or MRI examination. The sensitivity and speci-ficity of DWI were both 100% ,and those of conventional MRI was 20% and 100% ,respectively. The infarctional region on DWI appeared high intensity and it was in low intensity on ADC maps. Conclusion DWI combined with ADC maps can be an important index in the diagnosis of hyperacute cerebral infarction. Its accuracy for diagnosis was high, which provides objective proofs for early clinical thrombolysis treatment.